- Early Detection of Parkinson's From Biomarkers (FierceBiotech.com)
- "Scientists at Durin Technologies, Inc., and the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (UMDNJ-SOM) have announced a possible breakthrough in the search for a diagnostic biomarker for Parkinson's disease - a blood test that in the future may be able to detect the disease with high accuracy. The research team's findings appear online in PLoS ONE."
"Parkinson's disease is second most common neurodegenerative disease among older adults and there is widespread recognition that early detection would allow treatment that could slow its progression," said Robert Nagele, PhD, a professor of medicine at UMDNJ-SOM and the founder of Durin Technologies, Inc." 11-12
- Early Detection of Parkinson's From Biomarkers (MichaelJFox.org)
- "Misfolding and clumping of the alpha-synuclein protein in brain and body cells are the pathological hallmark of Parkinson’s disease. Scientists believe this toxic dysfunction gives rise to Parkinson’s onset and progression. The ability to visualize alpha-synuclein activity in the living brain would be a game-changer for testing and developing potential new Parkinson’s drugs. (Similar strategies in Alzheimer’s have had a major effect on accelerating drug development for that disease.)"
"Now AC Immune, a Swiss biotechnology company, has shared the first images of alpha-synuclein in the living human brain." 05-22
- Exosomes: Early Detection of Parkinson's From Biomarkers (ThermoFisher.com)
- Exosomes are about as close as we can get to the perfect diagnostic and therapeutic vehicle. They are immune-privileged, evading recognition and destruction by the immune system, thus limiting any potential immune-related safety issues.12 Many types of exosomes can permeate different tissue types, including the blood-brain barrier.13 That feature alone could make exosome delivery a feasible treatment course for brain cancers which are notoriously difficult to access and treat pharmacologically. It is also possible to use the type and contents of exosomes to diagnose diseases at an earlier stage (compared to traditional biopsy), determine the presence of certain tumor types, and track treatment efficacy, all from a simple serum sample.14"
"Now AC Immune, a Swiss biotechnology company, has shared the first images of alpha-synuclein in the living human brain." 05-22